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Aims:Many studies of human subjects have demonstrated the utility of assessing serum levels of endothelin-1
(ET-1) and big ET-1 as clinical biomarkers in cardiopulmonary and neoplastic diseases. In this study we explored
the feasibility of using serum big ET-1 as a reliable veterinary marker in dogs with various cardiopulmonary and
neoplastic diseases.
Main methods: Serum big ET-1 levels were measured by ELISA in dogs with cardiopulmonary (n = 21) and
neoplastic diseases (n = 57). Dogs exhibiting cardiopulmonary disease were divided into two groups based on
the velocity of tricuspid valve regurgitation (3.0 Nm/s) measured by ultrasound: without and with pulmonary
hypertension. Big ET-1 levels for the dogs with the diseases were compared with levels in normal healthy dogs
(n = 17).
Key ﬁndings: Dogs with cardiopulmonary disease (4.6 ± 4.6 pmol/l) showed a signiﬁcantly (P b 0.01) higher
level of big ET-1 than healthy control dogs (1.1 ± 0.53 pmol/l). Serum levels in the dogs with pulmonary
hypertension (6.2 ± 5.3 pmol/l) were signiﬁcantly (P b 0.01) higher than those without pulmonary hypertension
(2.0 ± 0.6 pmol/l). Dogs with hemangiosarcoma (5.6 ± 2.2 pmol/l), adenocarcinoma (2.0 ± 1.8 pmol/l),
histiocytic sarcoma (3.3 ± 1.9 pmol/l), chondrosarcoma or osteosarcoma (3.0 ± 1.6 pmol/l) and hepatocellular
carcinoma (2.7 ± 1.8 pmol/l) showed signiﬁcantly (P b 0.05) higher levels than healthy control dogs.
Signiﬁcance: These ﬁndings point to the potential of serum big ET-1 as a clinical marker for cardiopulmonary and
neoplastic diseases in dogs.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/ .0/).3IntroductionThere have been many studies reporting the importance of evaluat-
ing endothelin-1 (ET-1) or big ET-1 in blood as a clinical marker for var-
ious diseases, especially cardiopulmonary and neoplastic diseases in
human patients (Simpson et al., 2000; Yildirim et al., 2008; Ishikawa
et al., 1995a, 1995b;Miyauchi et al., 1989). In cardiopulmonary diseases
including cardiac valvular insufﬁciency, cardiomyopathy and primary
pulmonary hypertension, ET-1 and big ET-1 blood levels have been
reported to correlate with disease severity (Ishikawa et al., 1995a,
1995b; Miyauchi et al., 1989). In patients with tumors including breast,
hepatocellular, gastric and prostate cancer, blood levels have been
shown to elevate at an advanced stage with distant metastasis to the
lymph nodes or lungs (Yildirim et al., 2008; Nakamuta et al., 1993;
Ferrari-Bravo et al., 2000; Nelson et al., 1995). Prompted by these ﬁnd-
ings, clinicians have investigated the feasibility of using blood ET-1 and
big ET-1 levels as clinical markers for predicting prognosis, evaluating. This is an open access article undertherapeutic beneﬁt and diagnosing these diseases (Yildirim et al.,
2008; Nakamuta et al., 1993; Ferrari-Bravo et al., 2000; Nelson et al.,
1995). In veterinary medicine, however, there is less information on
the clinical signiﬁcance of blood ET-1 and big ET-1 levels.
In this study we investigated the potential of big ET-1 as a clinical
marker for canine cardiopulmonary and neoplastic diseases by compar-
ing serum levels in canine patients diagnosed with cardiopulmonary or
neoplastic disease through clinical and pathological examinations.
Serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP),
which is a reliable clinical marker for cardiac disease (Hori et al.,
2012), was also measured and compared with big ET-1 levels in dogs
with cardiopulmonary disease.Materials and methods
Dogs
Twenty-one dogs (eight female and thirteen male, average age
7.8 ± 3.6 years old, age range 5–13 years old) with cardiopulmonarythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ .0/).3
Fig. 1. Serum big ET-1 levels in dogs with cardiopulmonary diseases. Dogs with
cardiopulmonary diseases were divided into two groups, dogs without and with pulmo-
nary hypertension (PH), based on TR velocity measured by ultrasound. Serum big ET-1
levels were assessed in the groups without and with PH (groups with cardiopulmonary
disease), compared to those of healthy control group. Serum big ET-1 levels in the dogs
with the diseasewere signiﬁcantly (P b 0.01) higher than those of control dogs. Signiﬁcant
(P b 0.01) and remarkable increase was observed in dogs with PH compared to the group
without PH and healthy group. Each point represents an individual serum level. The
horizontal lines represent the means for each group.
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thirty two male, average age 8.9 ± 4.1 years old, age range 6–14 years
old), diagnosed at Rakuno Gakuen University Veterinary Teaching
Hospital during a period from April 2010 to July 2013, were enrolled in
this study. Seventeen healthy dogs (eleven female and six male, average
age 8.3 ± 3.4 years old, age range 4–10 years old) kept at Kitasato
University or Rakuno Gakuen University were used as controls. There
was no signiﬁcant difference in the results based on age or sex among
cardiopulmonary, neoplastic and control groups.
All experimental procedures in this study progressed under
approval by ethics committees in Kitasato and Rakuno Gakuen Univer-
sities (ethics committee approval numbers 10-028 and VH24A13,
respectively).
Diagnosis of cardiopulmonary and neoplastic diseases
Cardiopulmonary diseases were diagnosed by ultrasound with
sector probes (3 to 7.5 MHz) in conjunction with a scanner (EUB-
6500, HITACHIMedical Corporation, Tokyo, Japan) by three experienced
veterinarians in accordance with commonly recognized ultrasound
criteria. The cardiopulmonary disease studied was valvular (mitral and
tricuspid valves) insufﬁciency (twenty-one cases). The presence of
pulmonary hypertensionwas conﬁrmed based on tricuspid valve regur-
gitation (TR) velocity (3.0 N m/s) in accordance with previous reports
(Hori et al., 2012). Neoplastic diseases were diagnosed by histopatho-
logical examination using excised tumor tissues after surgery. The
neoplastic diseases enrolled in this study were hemangiosarcomas
(eight cases), malignant melanomas (eight cases), adenocarcinomas
(nine cases), histiocytic sarcoma (six cases), lymphomas (seven cases),
chondrosarcoma or osteosarcoma (four cases), mast cell tumors (four
cases), transitional cell carcinomas (three cases), hepatocellular carcino-
mas (four cases), gastrointestinal stromal tumor (one case), granulosa
cell tumor (one case), multiple myeloma (one case) and schwannoma
(one case). Because a decrease in renal excretion lengthens the half-
life of big ET-1 in blood (Rossi et al., 2013), dogs with renal disease
were excluded from this study based on blood tests and urinalysis.
Serum big ET-1 levels
Weprepared serum samples according tomethods described in pre-
vious studies (Yildirim et al., 2008; Rossi et al., 2013; Gruber et al., 2000;
Glaus et al., 2004). Brieﬂy, venous blood was collected in a serum sepa-
rating plastic tube. Immediately after centrifugation at 1200 g for 10min
at 4 °C, serum samples were stored at−80 °C until measurement.
Serum big ET-1 concentrations were assessed with a commercial
ELISA kit for human big ET-1 (Big ET-1 EIA Kit, IBL, Japan) after solid
phase extraction using Sep-Pak C18 cartridges (Waters, USA) according
to the manufacturer's protocol. This assay kit is demonstrated by
the manufacturer to have no signiﬁcant cross-reactivity (b0.1%) with
ET-1, ET-2, ET-3, big ET-2 or big ET-3. To show the feasibility of using a
human ELISA kit for estimation of canine big ET-1, we performed a dilu-
tion experiment (2n dilution) using canine serum samples. The resulting
curves obtained from the dilution experimentwere parallel to the stan-
dard curve. Linearity of the curves was observed between 0.18 and
23 pmol/l. To evaluate the intra-assay and inter-assay coefﬁcients of
variance, we measured three samples ﬁve times for three alternating
days. The intra-assay and inter-assay coefﬁcients of variance were
3.9% and 2.5% respectively. Serum NT-proBNP levels were measured
by a commercial laboratory (IDEXX Laboratories, Japan).
Statistical analysis
The Mann–Whitney U test was used to analyze differences in serum
big ET-1 or NT-pro BNP levels with P b 0.05 considered signiﬁcant.
Spearman's rank correlation coefﬁcientwas used to analyze the correla-
tion between serum big ET-1 levels and TR speeds. Data analyses werecarried out with Excel Toukei 2010 (SSRI, Tokyo, Japan). All data in
this study are shown as mean ± standard deviation.
Results
Serum NT-pro BNP and big ET-1 levels in cardiopulmonary disease
Dogs with cardiopulmonary disease were divided into two groups:
without and with pulmonary hypertension based on TR velocity mea-
sured by ultrasound. No signiﬁcant difference was observed in serum
NT-pro BNP levels between the two cardiopulmonary disease groups:
those without (848 ± 1018 pmol/l) and with (1398 ± 1746 pmol/l)
pulmonary hypertension. In contrast, serum big ET-1 levels were
signiﬁcantly (P b 0.01) elevated in dogs with pulmonary hypertension
(6.2± 5.3 pmol/l) compared to thosewithout pulmonary hypertension
(2.0 ± 0.6 pmol/l) (Fig. 1). Regardless of the presence or absence of
pulmonary hypertension, dogs with cardiopulmonary disease (4.6 ±
4.6 pmol/l) showed a signiﬁcantly (P b 0.01) higher level of big ET-1
than healthy controls (1.1 ± 0.49 pmol/l). Through correlation analysis
between the serum levels of NT-pro BNP or big ET-1 and TR velocity
values obtained by ultrasound, which represent systolic pulmonary
artery pressure, big ET-1 levels (R2 = 0.74, P b 0.01) were shown to
correlate better with the severity of pulmonary hypertension than NT-
pro BNP levels (R2 = 0.32, P = 0.24). These results suggest that
serum big ET-1 could be a more reliable clinical marker than serum
NT-pro BNP for detecting cardiopulmonary disease with pulmonary
hypertension in dogs.
Serum big ET-1 levels in neoplastic disease
To investigate the potential of big ET-1 as a tumor maker, we
assessed serum levels in dogs exhibiting various tumors. Serum big
ET-1 levels in dogs with hemangiosarcoma (5.6 ± 2.2 pmol/l), adeno-
carcinoma (2.0 ± 1.8 pmol/l), histiocytic sarcoma (3.3 ± 1.9 pmol/l),
chondrosarcomaor osteosarcoma (3.0±1.6 pmol/l) andhepatocellular
carcinoma (2.7 ± 1.8 pmol/l) were signiﬁcantly (P b 0.05) higher than
those in healthy control dogs (1.1 ± 0.53 pmol/l) (Fig. 2). Interestingly,
hemangiosarcoma, a tumor derived from vascular endothelial cells,
produced the highest level of all tumors examined.
Fig. 2. Serum big ET-1 levels in neoplastic diseases. Serum big ET-1 levelswere assessed in
healthy control dogs (Cont) and patient dogs with hemangiosarcoma (HSA), malignant
melanoma (MM), adenocarcinoma (AC), histiocytic sarcoma (HCS), lymphoma (LYM),
chondrosarcoma or osteosarcoma (CS/OS), mast cell tumor (MCT), transitional cell
carcinoma (TCC), hepatocellular carcinoma (HCC), gastrointestinal stromal tumor
(GIST), granulosa cell tumor (GCT), multiple myeloma (MYE) and schwannoma (CHW).
Serum big ET-1 levels in dogs with HSA, AC, HCS, CS/OS and HCC were signiﬁcantly
(P b 0.05) higher than those in healthy control dogs. Each point represents an individual
serum big ET-1 level. The horizontal lines represent the means for each group.
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diseases
To investigate the speciﬁcity of serum big ET-1 as a clinical marker,
we compared the levels among cardiopulmonary, neoplastic and
control groups (Fig. 3). As a result, we observed no signiﬁcant difference
in the levels between the cardiopulmonary (4.6 ± 4.6 pmol/l) and
neoplastic (2.5 ± 2.3 pmol/l) groups, although the groups with the
diseases showed a signiﬁcant (P b 0.01) and notable increase compared
with the control group (1.1 ± 0.53 pmol/l). These ﬁndings show that a
primary diagnosis for cardiopulmonary or neoplastic disease based on
clinical assessment is essential.
Discussion
The precursor form proBNP exists as a pro-hormone that is cleaved
into the inactive N-terminal fragment NT pro-BNP and active peptide
BNP prior to release into blood circulation (Hunt et al., 1997). NT pro-
BNP is, at present, used as a surrogate marker for the biologically activeFig. 3. Comparison of serum big ET-1 levels between cardiopulmonary and neoplastic
diseases. Serum big ET-1 levels were quantitatively assessed in healthy control dogs
(Cont) and patient dogs with neoplastic (ND) and cardiopulmonary (CPD) diseases.
Serum big ET-1 levels in dogs with cardiopulmonary and neoplastic diseases were signif-
icantly higher than those in healthy control dogs. No signiﬁcant difference was observed
between the cardiopulmonary and neoplastic groups. Each point represents an individual
serum big ET-1 level. The horizontal lines represent the means for each group.formBNPbecause thepeptide ismore stable in vivo than the active form
(Ichiki et al., 2013). Similarly, the biologically active form ET-1 is gener-
ated by enzymatic cleavage from the inactive precursor form big ET-1,
which is more stable in vivo than the active form (Hemsen et al.,
1995). BNP is produced by ventricular myocytes in response to ventric-
ularmyocyte stretch (Ichiki et al., 2013), while expression of preproET-1
mRNA and production of ET-1 increase mainly in the lung of human
patients with cardiopulmonary diseases in association with pulmonary
vascular remodeling (Gao et al., 2013; Wang et al., 2011). We have
previously demonstrated a substantial increase in preproET-1 mRNA
expression in the lungs of dogs with heartworm disease (diroﬁlariasis),
which commonly leads to severe pre-capillary pulmonary hypertension
due to the presence of nematodes within the pulmonary artery (Uchide
and Saida, 2005). Although elevated preproET-1mRNA expression was
also observed in canine heart tissues as a result of right heart overload
secondary to pulmonary hypertension, vascular structural changes
and overproduction of ET-1 in the lung could be closely associated
with the pulmonary hypertension. The considerable increase in serum
ET-1 levels observed in dogs with the diseases more likely arises from
severe and extensive histological changes in the lung rather than from
changes in the heart (Munnell et al., 1980; Schaub and Rawlings,
1980). Together with previous reports showing a deeper involvement
of ET-1 than BNP in pulmonary disease (Hori et al., 2012; Hemsen
et al., 1995) our ﬁndings that serum big ET-1 levels correlate with the
severity of pulmonary hypertension suggest that serum big ET-1 could
be more reliable than NT pro-BNP as a clinical marker for cardiopulmo-
nary disease with pulmonary hypertension in dogs.
In humanmedicine, many tumormakers, including prostate speciﬁc
antigen for prostate carcinomas, alpha-fetoprotein for hepatocellular
tumors, urine basic fetoprotein for bladder cancer, carcinoembryonic
antigen and breast carcinoma-associated antigen 225 for breast cancer
and cytokeratin 19 fragment for lung cancer, have been studied and
used clinically (Jansen et al., 2010; Morimoto et al., 2012; Imamura
et al., 2000; Esteban et al., 1994; Kaneko et al., 1995; Lee et al., 2013).
However in veterinary medicine, no reliable tumor marker is currently
available for clinical use. Our ﬁnding that serum big ET-1 increases in
a variety of canine tumors shows its promise as a tumor marker, as
has been the case in human medicine (Yildirim et al., 2008; Nakamuta
et al., 1993; Ferrari-Bravo et al., 2000; Nelson et al., 1995). In particular,
hemangiosarcoma drew our attention because it produced the highest
level of all tumors examined. This result could be explained by the fact
that HSA is a tumor originating from vascular endothelial cells that
have the ability to produce and secrete ET-1 (Smith, 2003; Abraham
et al., 2007; Yanagisawa et al., 1988). Another contributing factor may
be that disseminated intravascular coagulation occurs with high inci-
dence in canine HSA (Smith, 2003). Reports conﬁrming elevation of
serum ET-1 and big ET-1 in human patientswith disseminated intravas-
cular coagulation support this hypothesis (Ishibashi et al., 1991, 1994;
Asakura et al., 1992). An important next step is to examine serum big
ET-1 levels in dogs with disseminated intravascular coagulation in
order to better understand the speciﬁcity of big ET-1 as a tumor marker
for HSA.
Cardiopulmonary and neoplastic diseases are listed as major causes
of death in aged dogs (Bronson, 1982; Fleming et al., 2011). Serum big
ET-1 levels could aid diagnosis and treatment of these diseases in veter-
inary medicine. However, because there is no signiﬁcant difference in
serum big ET-1 levels between cardiopulmonary and neoplastic
patients, speciﬁc diagnostic assessment for each disease in combination
with other clinical modalities including X-ray, ultrasound and blood
tests would be an important ﬁrst step when using this peptide as a
clinical marker for diverse conditions.
Conclusion
We have investigated the potential of serum big ET-1 as a clinical
marker for canine cardiopulmonary and neoplastic diseases by
332 S. Fukumoto et al. / Life Sciences 118 (2014) 329–332comparing the serum levels in dogs diagnosed by clinical and patholog-
ical examinations. Although further studies are necessary, our ﬁndings
point to the potential of serum big ET-1 as an effective clinical marker
for cardiopulmonary and neoplastic diseases in dogs.
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